Cargando…
Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation
Aspartylglucosaminuria (AGU) is an autosomal recessive lysosomal storage disease caused by loss of the enzyme aspartylglucosaminidase (AGA), resulting in AGA substrate accumulation. AGU patients have a slow but progressive neurodegenerative disease course, for which there is no approved disease-modi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934581/ https://www.ncbi.nlm.nih.gov/pubmed/33186692 http://dx.doi.org/10.1016/j.ymthe.2020.11.012 |
_version_ | 1783660843629543424 |
---|---|
author | Chen, Xin Snanoudj-Verber, Sarah Pollard, Laura Hu, Yuhui Cathey, Sara S. Tikkanen, Ritva Gray, Steven J. |
author_facet | Chen, Xin Snanoudj-Verber, Sarah Pollard, Laura Hu, Yuhui Cathey, Sara S. Tikkanen, Ritva Gray, Steven J. |
author_sort | Chen, Xin |
collection | PubMed |
description | Aspartylglucosaminuria (AGU) is an autosomal recessive lysosomal storage disease caused by loss of the enzyme aspartylglucosaminidase (AGA), resulting in AGA substrate accumulation. AGU patients have a slow but progressive neurodegenerative disease course, for which there is no approved disease-modifying treatment. In this study, AAV9/AGA was administered to Aga(−/−) mice intravenously (i.v.) or intrathecally (i.t.), at a range of doses, either before or after disease pathology begins. At either treatment age, AAV9/AGA administration led to (1) dose dependently increased and sustained AGA activity in body fluids and tissues; (2) rapid, sustained, and dose-dependent elimination of AGA substrate in body fluids; (3) significantly rescued locomotor activity; (4) dose-dependent preservation of Purkinje neurons in the cerebellum; and (5) significantly reduced gliosis in the brain. Treated mice had no abnormal neurological phenotype and maintained body weight throughout the whole experiment to 18 months old. In summary, these results demonstrate that treatment of Aga(−/−) mice with AAV9/AGA is effective and safe, providing strong evidence that AAV9/AGA gene therapy should be considered for human translation. Further, we provide a direct comparison of the efficacy of an i.v. versus i.t. approach using AAV9, which should greatly inform the development of similar treatments for other related lysosomal storage diseases. |
format | Online Article Text |
id | pubmed-7934581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-79345812022-03-03 Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation Chen, Xin Snanoudj-Verber, Sarah Pollard, Laura Hu, Yuhui Cathey, Sara S. Tikkanen, Ritva Gray, Steven J. Mol Ther Original Article Aspartylglucosaminuria (AGU) is an autosomal recessive lysosomal storage disease caused by loss of the enzyme aspartylglucosaminidase (AGA), resulting in AGA substrate accumulation. AGU patients have a slow but progressive neurodegenerative disease course, for which there is no approved disease-modifying treatment. In this study, AAV9/AGA was administered to Aga(−/−) mice intravenously (i.v.) or intrathecally (i.t.), at a range of doses, either before or after disease pathology begins. At either treatment age, AAV9/AGA administration led to (1) dose dependently increased and sustained AGA activity in body fluids and tissues; (2) rapid, sustained, and dose-dependent elimination of AGA substrate in body fluids; (3) significantly rescued locomotor activity; (4) dose-dependent preservation of Purkinje neurons in the cerebellum; and (5) significantly reduced gliosis in the brain. Treated mice had no abnormal neurological phenotype and maintained body weight throughout the whole experiment to 18 months old. In summary, these results demonstrate that treatment of Aga(−/−) mice with AAV9/AGA is effective and safe, providing strong evidence that AAV9/AGA gene therapy should be considered for human translation. Further, we provide a direct comparison of the efficacy of an i.v. versus i.t. approach using AAV9, which should greatly inform the development of similar treatments for other related lysosomal storage diseases. American Society of Gene & Cell Therapy 2021-03-03 2020-11-11 /pmc/articles/PMC7934581/ /pubmed/33186692 http://dx.doi.org/10.1016/j.ymthe.2020.11.012 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Chen, Xin Snanoudj-Verber, Sarah Pollard, Laura Hu, Yuhui Cathey, Sara S. Tikkanen, Ritva Gray, Steven J. Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation |
title | Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation |
title_full | Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation |
title_fullStr | Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation |
title_full_unstemmed | Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation |
title_short | Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation |
title_sort | pre-clinical gene therapy with aav9/aga in aspartylglucosaminuria mice provides evidence for clinical translation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934581/ https://www.ncbi.nlm.nih.gov/pubmed/33186692 http://dx.doi.org/10.1016/j.ymthe.2020.11.012 |
work_keys_str_mv | AT chenxin preclinicalgenetherapywithaav9againaspartylglucosaminuriamiceprovidesevidenceforclinicaltranslation AT snanoudjverbersarah preclinicalgenetherapywithaav9againaspartylglucosaminuriamiceprovidesevidenceforclinicaltranslation AT pollardlaura preclinicalgenetherapywithaav9againaspartylglucosaminuriamiceprovidesevidenceforclinicaltranslation AT huyuhui preclinicalgenetherapywithaav9againaspartylglucosaminuriamiceprovidesevidenceforclinicaltranslation AT catheysaras preclinicalgenetherapywithaav9againaspartylglucosaminuriamiceprovidesevidenceforclinicaltranslation AT tikkanenritva preclinicalgenetherapywithaav9againaspartylglucosaminuriamiceprovidesevidenceforclinicaltranslation AT graystevenj preclinicalgenetherapywithaav9againaspartylglucosaminuriamiceprovidesevidenceforclinicaltranslation |